Q32 Bio Inc. (QTTB) shareholders
Close on Nov 17, 2026Market cap $256.91MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vii LLC (11.80%) | 4,127,987 | 13.90% | 13D (active) amendment | Jul 16, 2026 |
| Aaron Davis Joint filing with Boxer Capital Management, LLC (13.30%), Boxer Holdings, LP (13.30%) and 1 more | 3,149,310 | 13.30% | 13G (passive) | Jun 30, 2026 |
| ADAR1 Partners, LP Joint filing with ADAR1 Capital Management, LLC (5.40%), ADAR1 Capital Management GP, LLC (5.40%) and 1 more | 3,120,824 | 5.40% | 13G (passive) | Mar 4, 2024 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 2,367,524 | 9.99% | 13G (passive) | May 28, 2026 |
| Boxer Capital Management, LLC Joint filing with Boxer Holdings, LP (7.90%), Boxer Holdings GP, LLC (7.90%) and 1 more | 2,357,922 | 7.90% | 13G (passive) amendment | Sep 30, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.80%), Peter Kolchinsky (9.80%) and 1 more | 2,332,457 | 9.80% | 13G (passive) | May 28, 2026 |
| Orbimed Capital Gp Vii LLC Joint filing with Orbimed Advisors LLC (15.40%) | 2,252,987 | 15.40% | 13D (active) amendment | Feb 18, 2026 |
| Bank Of America Corp /De/ | 2,205,390 | 7.40% | 13G (passive) | Sep 30, 2026 |
| Fhmlsp, L.L.C. Joint filing with Frazier Life Sciences Public Fund, L.P. (5.90%), Fhmlsp, L.P. (5.90%) | 1,755,116 | 5.90% | 13G (passive) | Oct 2, 2026 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (5.70%), Steven A. Cohen (5.70%) | 958,768 | 5.70% | 13G (passive) amendment | Mar 31, 2026 |
| Opaleye Management Inc. Joint filing with Opaleye, L.P. (5.49%), James Silverman (5.49%) | 931,000 | 5.49% | 13G (passive) amendment | Jun 30, 2026 |
| Acorn Capital Advisors, GP, LLC Joint filing with Acorn Bioventures, L.P. (6.70%), Anders Hove (6.70%) | 803,425 | 6.70% | 13D (active) | Mar 25, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of QTTB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 4,127,987 | 13.87% | $52.59M | +1,875,000 | 0.97% |
| Boxer Capital Management, LLC | 3,149,310 | 10.58% | $40.12M | New | 3.02% |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | 9.13% | $34.62M | +625,000 | 3.93% |
| Bvf Inc/Il | 2,350,000 | 7.89% | $29.94M | New | 0.77% |
| Ra Capital Management, L.P. | 2,332,457 | 7.84% | $29.72M | New | 0.26% |
| Point72 Asset Management, L.P. | 1,173,396 | 3.94% | $14.95M | New | 0.02% |
| Opaleye Management Inc. | 931,000 | 3.13% | $11.86M | −325,228 | 1.07% |
| Logos Global Management LP | 800,000 | 2.69% | $10.19M | New | 0.44% |
| SummitTX Capital, L.P. | 733,774 | 2.46% | $9.35M | New | 0.24% |
| Vanguard Capital Management LLC | 518,803 | 1.74% | $6.61M | +212,402 | 0.00% |
| Ikarian Capital, LLC | 430,000 | 1.44% | $5.48M | New | 0.59% |
| Woodline Partners LP | 286,212 | 0.96% | $3.65M | New | 0.01% |
| American Century Companies Inc | 272,752 | 0.92% | $3.47M | +253,982 | 0.00% |
| Sanofi | 244,083 | 0.82% | $3.11M | – | 0.58% |
| Acadian Asset Management LLC | 218,234 | 0.73% | $2.78M | +45,648 | 0.00% |
| Acorn Capital Advisors, LLC | 216,171 | 0.73% | $2.75M | −98,881 | 0.75% |
| Renaissance Technologies LLC | 179,600 | 0.60% | $2.29M | −27,315 | 0.00% |
| Jane Street Group, LLC | 162,747 | 0.55% | $2.07M | +97,148 | 0.00% |
| Monimus Capital Management, LP | 132,036 | 0.44% | $1.68M | −2,274 | 0.39% |
| Boothbay Fund Management, LLC | 130,427 | 0.44% | $1.66M | New | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 71 | 22M | 74.6% | 27 / 18 | 13 / 8 | 15M | 2M |
| Q1 2026 | 53 | 9M | 31.7% | 11 / 14 | 9 / 8 | 2M | 1M |
| Q4 2025 | 52 | 8M | 27.0% | 7 / 9 | 20 / 8 | 0M | 1M |
| Q3 2025 | 53 | 8M | 28.3% | 8 / 10 | 18 / 16 | 0M | 1M |
| Q2 2025 | 61 | 9M | 30.2% | 10 / 12 | 19 / 22 | 0M | 1M |
| Q1 2025 | 73 | 9M | 31.6% | 8 / 17 | 20 / 26 | 0M | 2M |
| Q4 2024 | 92 | 11M | 36.9% | 40 / 22 | 10 / 21 | 4M | 2M |
| Q3 2024 | 73 | 9M | 30.6% | 28 / 18 | 8 / 8 | 2M | 1M |
| Q2 2024 | 54 | 8M | 27.1% | 20 / 16 | 6 / 4 | 1M | 0M |
| Q1 2024 | 38 | 7M | 25.0% | 38 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
24 funds held QTTB in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of QTTB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 389,115 | 1.31% | $4.96M | 0.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 128,510 | 0.43% | $1.42M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 119,269 | 0.40% | $1.52M | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 34,613 | 0.12% | $440.97K | 0.45% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 30,017 | 0.10% | $331.69K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 29,465 | 0.10% | $375.38K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 16,801 | 0.06% | $185.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 15,339 | 0.05% | $169.50K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 14,652 | 0.05% | $229.74K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,325 | 0.03% | $91.99K | 0.00% | May 31, 2026 |
| Small-Cap Value Portfolio | 6,223 | 0.02% | $79.28K | 0.02% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 5,934 | 0.02% | $75.60K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 4,890 | 0.02% | $76.68K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 4,485 | 0.02% | $57.14K | 0.00% | Jun 30, 2026 |
| Column Small Cap Fund | 1,976 | 0.01% | $21.83K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jodie Pope Morrison | CEO, Director | 340,038 | 1.14% | Oct 14, 2026 |
| Lee Kalowski | CFO and President | 137,170 | 0.46% | Oct 14, 2026 |
| Shelia M. Violette | Chief Scientific Officer | 163,131 | 0.55% | Oct 14, 2026 |
| Jason Campagna | Chief Medical Officer | 37,500 | 0.13% | Feb 26, 2025 |
| Mary Thistle | Director | – | – | Jul 21, 2026 |
| David S. Grayzel | Director | 2,092,106 | 7.03% | Jul 21, 2026 |
| Kathleen Laporte | Director | 5,431 | 0.02% | Jul 21, 2026 |
| Diyong Xu | Director, 10% owner | 625,000 | 2.10% | Jul 21, 2026 |
| Mark T. Iwicki | Director | – | – | Jul 21, 2026 |
| Arthur Tzianabos | Director | 7,983 | 0.03% | Jul 21, 2026 |
| Sven Ante Lundberg | Director | 1,200 | 0.00% | Jul 21, 2026 |
| Isaac Manke | Director | 53,521 | 0.18% | Jul 21, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | – | – | Jun 1, 2026 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | 3,502,987 | 11.77% | Jun 1, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 2,252,987 | 7.57% | Jun 1, 2026 |
| Atlas Venture Associates Opportunity III, L.P. | – | 625,000 | 2.10% | Jun 8, 2026 |
| Atlas Venture Opportunity Fund Ill, L.P. | – | – | – | Jun 8, 2026 |
| Atlas Venture Associates Opportunity III, LLC | – | – | – | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison CEO, Director | Oct 6, 2026 | Sale | −3,221 | $8.32 | $26.80K | 340,038 |
| Shelia M. Violette Chief Scientific Officer | Oct 6, 2026 | Sale | −917 | $8.32 | $7.63K | 126,854 |
| Lee Kalowski CFO and President | Oct 6, 2026 | Sale | −1,301 | $8.32 | $10.82K | 137,170 |
| Jodie Pope Morrison CEO, Director | Aug 25, 2026 | Sale | −9,845 | $16.56 | $163.03K | 343,259 |
| Shelia M. Violette Chief Scientific Officer | Aug 25, 2026 | Sale | −2,798 | $16.56 | $46.33K | 127,771 |
| Lee Kalowski CFO and President | Aug 25, 2026 | Sale | −3,972 | $16.56 | $65.78K | 138,471 |
| Lee Kalowski CFO and President | Jul 16, 2026 | Award | +53,250 | – | – | 142,443 |
| Jodie Pope Morrison CEO, Director | Jul 16, 2026 | Award | +132,000 | – | – | 353,104 |
| Shelia M. Violette Chief Scientific Officer | Jul 16, 2026 | Award | +37,500 | – | – | 130,569 |
| Isaac Manke Director | Jun 30, 2026 | Option exercise | +53,521 | $2.80 | $149.86K | 53,521 |
| Capital GP VII LLC OrbiMed Director, 10% owner | May 28, 2026 | Buy | +1,250,000 | $8.00 | $10.00M | 3,502,987 |
| Capital GP VII LLC OrbiMed Director, 10% owner | May 28, 2026 | Buy | +625,000 | $8.00 | $5.00M | 625,000 |
| Diyong Xu Director, 10% owner | May 28, 2026 | Buy | +625,000 | $8.00 | $5.00M | 625,000 |
| Diyong Xu Director, 10% owner | May 28, 2026 | Buy | +1,250,000 | $8.00 | $10.00M | 3,502,987 |
| Jodie Pope Morrison CEO, Director | Feb 25, 2026 | Sale | −9,896 | $4.51 | $44.63K | 89,104 |
| Lee Kalowski CFO and President | Feb 25, 2026 | Sale | −3,995 | $4.51 | $18.02K | 35,943 |
| Shelia M. Violette Chief Scientific Officer | Feb 25, 2026 | Sale | −2,815 | $4.51 | $12.70K | 55,569 |
| Jodie Pope Morrison CEO, Director | Feb 24, 2026 | Award | +132,000 | – | – | 221,104 |
| Lee Kalowski CFO and President | Feb 24, 2026 | Award | +53,250 | – | – | 89,193 |
| Shelia M. Violette Chief Scientific Officer | Feb 24, 2026 | Award | +37,500 | – | – | 93,069 |
| Jodie Pope Morrison CEO, Director | Dec 2, 2025 | Sale | −22,506 | $3.46 | $77.87K | 99,000 |
| Lee Kalowski CFO and President | Dec 2, 2025 | Sale | −9,072 | $3.46 | $31.39K | 39,938 |
| Shelia M. Violette Chief Scientific Officer | Aug 26, 2025 | Sale | −2,990 | $1.80 | $5.38K | 58,384 |
| Lee Kalowski CFO and President | Aug 26, 2025 | Sale | −4,240 | $1.80 | $7.63K | 49,010 |
| Jodie Pope Morrison CEO, Director | Aug 26, 2025 | Sale | −10,494 | $1.80 | $18.89K | 121,506 |
| Lee Kalowski CFO and President | Feb 24, 2025 | Award | +53,250 | – | – | 53,250 |
| Jason Campagna Chief Medical Officer | Feb 24, 2025 | Award | +37,500 | – | – | 37,500 |
| Jodie Pope Morrison CEO, Director | Feb 24, 2025 | Award | +132,000 | – | – | 132,000 |
| Shelia M. Violette Chief Scientific Officer | Feb 24, 2025 | Award | +37,500 | – | – | 61,374 |
| Shelia M. Violette Chief Scientific Officer | Oct 15, 2024 | Option exercise | +6,000 | $7.29 | $43.74K | 23,874 |
| Shelia M. Violette Chief Scientific Officer | Oct 11, 2024 | Option exercise | +4,574 | $3.12 | $14.27K | 17,874 |
| Shelia M. Violette Chief Scientific Officer | Oct 8, 2024 | Option exercise | +13,300 | $3.12 | $41.50K | 13,300 |
| Arthur Tzianabos Director | Mar 25, 2024 | Sale | −265 | $24.20 | $6.41K | 7,983 |
| Arthur Tzianabos Director | Mar 25, 2024 | Option exercise | +1,095 | – | – | 8,248 |
| Paul Alloway See Remarks | Mar 25, 2024 | Sale(10b5-1 plan) | −268 | $24.21 | $6.49K | 2,596 |
| Charles Michaud Jr See Remarks | Mar 25, 2024 | Sale(10b5-1 plan) | −75 | $24.20 | $1.82K | 927 |
| Charles Michaud Jr See Remarks | Mar 25, 2024 | Option exercise | +6,448 | – | – | 18,046 |
| Paul Alloway See Remarks | Mar 25, 2024 | Option exercise | +23,530 | – | – | 51,566 |
| Arthur Tzianabos Director | Jan 9, 2024 | Sale(10b5-1 plan) | −13,037 | $0.57 | $7.43K | 128,778 |
| Paul Alloway See Remarks | Jan 3, 2024 | Sale(10b5-1 plan) | −7,280 | $0.57 | $4.15K | 28,036 |
| Charles Michaud Jr See Remarks | Jan 3, 2024 | Sale(10b5-1 plan) | −1,708 | $0.57 | $974 | 11,598 |
| Arthur Tzianabos Director | Jan 1, 2024 | Option exercise | +14,280 | – | – | 122,675 |
| Arthur Tzianabos Director | Jan 1, 2024 | Option exercise | +19,140 | – | – | 141,815 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +1,056 | – | – | 10,666 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +2,640 | – | – | 13,306 |
| Charles Michaud Jr See Remarks | Jan 1, 2024 | Option exercise | +544 | – | – | 9,610 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +8,910 | – | – | 35,316 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +4,420 | – | – | 21,126 |
| Paul Alloway See Remarks | Jan 1, 2024 | Option exercise | +5,280 | – | – | 26,406 |
| Albert Seymour See Remarks, Director | Sep 6, 2023 | Sale(10b5-1 plan) | −1,448 | $1.15 | $1.67K | 150,874 |
| Albert Seymour See Remarks, Director | Sep 6, 2023 | Option exercise | +4,620 | – | – | 152,322 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −109 | $1.39 | $152 | 4,160 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +387 | – | – | 4,269 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −1,308 | $1.39 | $1.82K | 7,496 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +1,548 | – | – | 4,318 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −436 | $1.39 | $606 | 3,882 |
| Julie Jordan Chief Medical Officer | Aug 3, 2023 | Option exercise | +4,644 | – | – | 8,804 |
| Julie Jordan Chief Medical Officer | Aug 2, 2023 | Option exercise | +350 | – | – | 2,869 |
| Julie Jordan Chief Medical Officer | Aug 2, 2023 | Sale(10b5-1 plan) | −99 | $1.31 | $130 | 2,770 |
| Paul Alloway See Remarks | Mar 2, 2023 | Sale(10b5-1 plan) | −10,965 | $1.45 | $15.90K | 16,706 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Q32 Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46,559 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lee Kalowski Officer | Dec 2, 2025 | 9,072 | $31.40K | Dec 2, 2025 | Restricted Stock |
| Jodie Pope Morrison Officer, Director | Dec 2, 2025 | 22,506 | $77.87K | Dec 2, 2025 | Restricted Stock |
See a number that looks wrong?